Results 141 to 150 of about 8,073 (181)

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

Annals of Hematology, 2012
Cytogenetic analyses of chronic myelogenous leukemia (CML) have been performed previously in a large number of reports, but systematical research based on large sample sizes from the Chinese population is seldom available. In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center
Qitian Mu, Jie Jin, Ying Lu, Xiangmin Tong, Feifei Chen, Zhimei Chen, Yungui Wang, Qiuling Ma, Qiuling Ma   +8 more
openaire   +2 more sources

The Relationship Between the Type ofbcr-ablHybrid Messenger RNA and Thrombopoiesis in Philadelphia-Positive Chronic Myelogenous Leukemia

Leukemia & Lymphoma, 1993
Formation of the Philadelphia (Ph1) chromosome, which contains the hybrid bcr-abl gene, is thought to be the initial event in chronic myelogenous leukemia (CML). The positions of the breakpoint within the breakpoint cluster region (bcr) on the bcr-abl gene in 22 chronic-phase cases of Ph1-positive CML were determined using conventional Southern blots ...
Takeo Nomura, Koiti Inokuchi
openaire   +3 more sources

Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in philadelphia-positive chronic myelogenous leukemia

Leukemia Research, 1992
We studied the type of bcr-abl mRNA for 34 patients with chronic myelogenous leukemia and analyzed for correlations among the mRNA type, the clinical outcome and the transforming activity using the tumorigenicity assay. There was no difference in the distribution of the mRNA-types (b2-a2 and b3-a2) between clinical phases.
Takeo Nomura, Kazuo Dan, Hiroki Matsuoka, Koichi Miyake, Koiti Inokuchi, Makoto Futaki   +5 more
openaire   +3 more sources

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL-Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Blood, 2012
Abstract Abstract 2832 Co-occurrence of a JAK2 V617F-positive myeloproliferative neoplasm (MPN) with BCR-ABL-positive chronic myelogenous leukemia (CML) in a single patient is rare. Previous reports have suggested that the two disorders may arise independently or within the same clone, but definitive clonal analysis has ...
Deborah M. Moore, Daniel A.C. Fisher, Jonathan L. Klein, Stephen T. Oh, Li He, Eric M. Knoche, Gregory Rippberger   +6 more
openaire   +2 more sources

Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up

Cancer Genetics and Cytogenetics, 2006
The case of an 11-year-old child with adult-type chronic myeloid leukemia, Philadelphia (BCR-ABL) positive, reverse transcription-polymerase chain reaction negative for the major, minor, and micro breakpoints is presented. In the course of 3 years, the child failed to respond to treatment with hydroxyurea, refused all therapy for 6 months, was ...
Asher Moser, Ginat Narkis, Esther Manor, Joseph Kapelushnik   +3 more
openaire   +3 more sources

Presence or Re-Appearance of BCR-ABL-Positive Cells Years after Allogeneic Bone Marrow Transplantation for Chronic-Phase Chronic Myelogenous Leukemia in Patients in Hematological Remission

Acta Haematologica, 1994
Allogeneic bone marrow transplantation (BMT) is considered to be the only curative therapy for chronic myelogenous leukemia (CML). The cytogenetic marker of CML, the Philadelphia (Ph) chromosome, or the molecular alterations caused by the BCR-ABL gene fusion can be used to monitor the success of treatment.
U.W. Schaefer, R. Bützler, K. Quabeck, L. Diekmann, Reinhard Becher, H. Schulte Holthausen, B. Opalka, Dietrich W. Beelen   +7 more
openaire   +3 more sources

Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival.

Leukemia, 1989
Despite the major breakthrough in the knowledge of the molecular events underlying the t(9;22) translocation, still no consistent data have been found on the evolution of Ph1 positive CML from the chronic to the accelerated or blastic phase of the disease.
Selleri L., Emilia G., Temperani P., Grassilli E., Zucchini P., Tagliafico E., Bonati A., Venezia L., Ferrari S., Torelli U., Torelli G.   +10 more
openaire   +2 more sources

A Population (Registry) Based Analysis of the Impact of Bcr-Abl Specific Tyrosine Kinase Inhibition on Survival after Diagnosis of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia..

Blood, 2008
Abstract Specific tyrosine kinase inhibition (TKI) of the bcr-abl fusion protein in Philadelphia chromosome positive chronic myelogenous leukemia (CML) was introduced into general use in 2000 after a plenary abstract presentation to ASH in December 1999.
Anmmd Kamruzzaman, Nanette Cox-Kennett, Loree Larratt, Deborah A. Rusnak, Joanne D. Hewitt, A. Robert Turner, Andrew Belch   +6 more
openaire   +2 more sources

Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP)

Journal of Clinical Oncology, 2006
6591 Background: AMN107 is a novel, highly selective oral Bcr-Abl inhibitor which is 20–50-fold more potent than imatinib. High response rates with AMN107 were observed in all CML phases post imatinib failure. Methods: Study Aims: Evaluate the efficacy of AMN107in newly diagnosed Ph-positive CML-CP.
G. Garcia-Manero, A. Salvado, S. O'Brien, Francis J. Giles, Laurie Letvak, E. Jabbour, J. E. Cortes, Hagop M. Kantarjian, G. Borthakur, Farhad Ravandi   +9 more
openaire   +2 more sources

Preliminary Activity of Nilotinib (AMN107), a Novel Selective Potent Oral Bcr-Abl Tyrosine Kinase Inhibitor, in Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Phase Chronic Myelogenous Leukemia (CML-CP).

Blood, 2006
Nilotinib is a novel, highly selective oral Bcr-Abl inhibitor which is approximately 30-fold more potent than imatinib. High response rates with nilotinib were observed in all CML phases post imatinib failure. We evaluated the efficacy of nilotinib in newly diagnosed Ph-positive CML-CP.
Laurie Letvak, Laurie Letvak, Elias Jabbour, Hagop M. Kantarjian, Susan O'Brien, Jorge E. Cortes, Francis J. Giles   +6 more
openaire   +2 more sources